Lumida
/AMLX
⌘K
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc

AMLX
$17.75USD+4.29%+0.73 today

MARKET CAP

2.0B

P/E (TTM)

FWD P/E

DAY RANGE

$17 – $18

52W RANGE

$7
$19

AI Summary

Stalk
StalkMedium

AMLX remains in a Stage 2 advancing corrective reset with clear higher highs and higher lows above rising EMAs, supporting a medium-term bullish bias. However, overbought conditions and a recent pullback into the 9- and 21-EMA zone advise patience. Execution should be deferred, stalking for acceptance and shallow pullbacks into the rising EMAs to participate in the ongoing trend.

  • Targets 160,000 US PBH patients addressing major unmet medical need
  • Phase III Lucidity trial completes in Q3 2026, paving FDA NDA submission
  • Q1 2026 EPS loss $0.37 misses consensus $0.33 target
Full analysis →
Insider Trades64 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 9, 2026SellAMLXGina MazzarielloChief Legal Officer30,000$17.96$2.0B-7.31%+137.30%$538.9K-7.44%10b5-1Buy Now
Mar 2, 2026SellAMLXCamille L BedrosianChief Medical Officer6,461$14.58$2.0B-7.31%+137.30%$94.2K-3.68%Buy Now
Mar 2, 2026SellAMLXGina MazzarielloChief Legal Officer6,844$14.52$2.0B-7.31%+137.30%$99.4K-4.84%Buy Now
Mar 2, 2026SellAMLXJames M FratesChief Financial Officer7,909$14.52$2.0B-7.31%+137.30%$114.9K-4.56%Buy Now
Mar 2, 2026SellAMLXJustin B. KleeCo-Chief Executive Officer29,282$14.47$2.0B-7.31%+137.30%$423.8K-0.87%Buy Now
Mar 2, 2026SellAMLXJoshua B CohenCo-Chief Executive Officer29,282$14.48$2.0B-7.31%+137.30%$424.1K-0.87%Buy Now
Feb 23, 2026SellAMLXGina MazzarielloChief Legal Officer3,419$14.14$2.0B-7.31%+137.30%$48.4K-2.36%Buy Now
Feb 2, 2026SellAMLXGina MazzarielloChief Legal Officer3,448$14.65$2.0B-7.31%+137.30%$50.5K-2.33%Buy Now
Feb 2, 2026SellAMLXJames M FratesChief Financial Officer3,557$14.65$2.0B-7.31%+137.30%$52.1K-2.01%Buy Now
Feb 2, 2026SellAMLXJoshua B CohenCo-Chief Executive Officer15,500$14.68$2.0B-7.31%+137.30%$227.6K-0.46%Buy Now
Feb 2, 2026SellAMLXJustin B. KleeCo-Chief Executive Officer15,500$14.69$2.0B-7.31%+137.30%$227.6K-0.46%Buy Now
Jan 15, 2026BuyAMLXJustin B. KleeCo-Chief Executive Officer338,188$10.03$2.0B-7.31%+137.30%$3.4M+0.45%Buy Now
Jan 15, 2026BuyAMLXJoshua B CohenCo-Chief Executive Officer338,167$10.03$2.0B-7.31%+137.30%$3.4M+0.45%Buy Now
Jan 6, 2026SellAMLXJames M FratesChief Financial Officer3,326$11.11$2.0B-7.31%+137.30%$37.0K-1.84%Buy Now
Jan 6, 2026SellAMLXJustin B. KleeCo-Chief Executive Officer7,715$11.09$2.0B-7.31%+137.30%$85.6K-0.23%Buy Now
Jan 6, 2026SellAMLXJoshua B CohenCo-Chief Executive Officer7,715$11.09$2.0B-7.31%+137.30%$85.6K-0.23%Buy Now
Dec 1, 2025SellAMLXCamille L BedrosianChief Medical Officer6,580$14.35$2.0B-7.31%+137.30%$94.4K-3.61%Buy Now
Sep 30, 2025SellAMLXGina MazzarielloChief Legal Officer8,828$14.58$2.0B-7.31%+137.30%$128.7K-5.62%Buy Now
Sep 30, 2025SellAMLXJames M FratesChief Financial Officer10,558$14.65$2.0B-7.31%+137.30%$154.7K-3.63%Buy Now
Sep 30, 2025SellAMLXCamille L BedrosianChief Medical Officer12,039$14.58$2.0B-7.31%+137.30%$175.5K-6.19%Buy Now
Sep 30, 2025SellAMLXJoshua B CohenCo-Chief Executive Officer29,933$14.35$2.0B-7.31%+137.30%$429.5K-0.45%Buy Now
Sep 30, 2025SellAMLXJustin B. KleeCo-Chief Executive Officer29,975$14.38$2.0B-7.31%+137.30%$431.0K-0.45%Buy Now
Aug 12, 2025SellAMLXGina MazzarielloChief Legal Officer30,000